These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 28098391)

  • 1. Understanding the formidable nail barrier: A review of the nail microstructure, composition and diseases.
    Baswan S; Kasting GB; Li SK; Wickett R; Adams B; Eurich S; Schamper R
    Mycoses; 2017 May; 60(5):284-295. PubMed ID: 28098391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation and
    Lee BC; Pangeni R; Na J; Koo KT; Park JW
    Drug Deliv; 2019 Dec; 26(1):1167-1177. PubMed ID: 31738083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microstructural alterations in the onychomycotic and psoriatic nail: Relevance in drug delivery.
    Cutrín Gómez E; Anguiano Igea S; Delgado-Charro MB; Gómez Amoza JL; Otero Espinar FJ
    Eur J Pharm Biopharm; 2018 Jul; 128():48-56. PubMed ID: 29673870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An investigation of how fungal infection influences drug penetration through onychomycosis patient's nail plates.
    McAuley WJ; Jones SA; Traynor MJ; Guesné S; Murdan S; Brown MB
    Eur J Pharm Biopharm; 2016 May; 102():178-84. PubMed ID: 26969264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Permeation studies of novel terbinafine formulations containing hydrophobins through human nails in vitro.
    Vejnovic I; Huonder C; Betz G
    Int J Pharm; 2010 Sep; 397(1-2):67-76. PubMed ID: 20620203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transungual delivery of efinaconazole: its deposition in the nail of onychomycosis patients and in vitro fungicidal activity in human nails.
    Sakamoto M; Sugimoto N; Kawabata H; Yamakawa E; Kodera N; Pillai R; Tatsumi Y
    J Drugs Dermatol; 2014 Nov; 13(11):1388-92. PubMed ID: 25607707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment and management strategies of onychomycosis.
    Aggarwal R; Targhotra M; Kumar B; Sahoo PK; Chauhan MK
    J Mycol Med; 2020 Jun; 30(2):100949. PubMed ID: 32234349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The low keratin affinity of efinaconazole contributes to its nail penetration and fungicidal activity in topical onychomycosis treatment.
    Sugiura K; Sugimoto N; Hosaka S; Katafuchi-Nagashima M; Arakawa Y; Tatsumi Y; Jo Siu W; Pillai R
    Antimicrob Agents Chemother; 2014 Jul; 58(7):3837-42. PubMed ID: 24752277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancing transungual delivery and spreading of efinaconazole under the nail plate through a unique formulation approach.
    Kircik LH
    J Drugs Dermatol; 2014 Dec; 13(12):1457-61. PubMed ID: 25607788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ciclopirox delivery into the human nail plate using novel lipid diffusion enhancers.
    Hafeez F; Hui X; Selner M; Rosenthal B; Maibach H
    Drug Dev Ind Pharm; 2014 Jun; 40(6):838-44. PubMed ID: 23600655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Onychomycosis: Current Understanding and Strategies for Enhancing Drug Delivery into Human Nail Tissue.
    Aslam R; Hussain T; Yousaf AM; Ghori MU; Khan IU; Rizvi SAA; Shahzad Y
    Curr Drug Res Rev; 2021; 13(1):25-35. PubMed ID: 32735534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transungual permeation: current insights.
    Bhuptani RS; Deshpande KM; Patravale VB
    Drug Deliv Transl Res; 2016 Aug; 6(4):426-39. PubMed ID: 26419676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and pharmacokinetic studies of continuous itraconazole for the treatment of onychomycosis.
    Kawada A; Aragane Y; Tezuka T
    J Dermatol; 2004 Feb; 31(2):104-8. PubMed ID: 15160863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of topical therapeutics for management of onychomycosis and other nail disorders: a pharmaceutical perspective.
    Elsayed MM
    J Control Release; 2015 Feb; 199():132-44. PubMed ID: 25481439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancing the nail permeability of topically applied drugs.
    Murdan S
    Expert Opin Drug Deliv; 2008 Nov; 5(11):1267-82. PubMed ID: 18976136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a novel penetration enhancer on the ungual permeation of two antifungal agents.
    Traynor MJ; Turner RB; Evans CR; Khengar RH; Jones SA; Brown MB
    J Pharm Pharmacol; 2010 Jun; 62(6):730-7. PubMed ID: 20636860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trans-ungual iontophoretic delivery of terbinafine.
    Nair AB; Vaka SR; Sammeta SM; Kim HD; Friden PM; Chakraborty B; Murthy SN
    J Pharm Sci; 2009 May; 98(5):1788-96. PubMed ID: 18781625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pharmaceutics perspective on drug delivery to the nail: recent advances and challenges.
    Delgado-Charro MB
    Ther Deliv; 2015 Jul; 6(7):773-5. PubMed ID: 26228770
    [No Abstract]   [Full Text] [Related]  

  • 19. Topical application of acidified nitrite to the nail renders it antifungal and causes nitrosation of cysteine groups in the nail plate.
    Finnen MJ; Hennessy A; McLean S; Bisset Y; Mitchell R; Megson IL; Weller R
    Br J Dermatol; 2007 Sep; 157(3):494-500. PubMed ID: 17627796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of ciclopirox nail lacquer with enhanced permeation and retention.
    Thapa RK; Choi JY; Go TG; Kang MH; Han SD; Jun JH; Son MW; Yong CS; Kim JO
    Arch Pharm Res; 2016 Jul; 39(7):953-9. PubMed ID: 27306785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.